TherapeuticsMD (NASDAQ:TXMD) Stock Price Down 0.9% – Here’s Why

TherapeuticsMD, Inc. (NASDAQ:TXMD)’s share price fell 0.9% on Tuesday . The stock traded as low as $2.28 and last traded at $2.29. 12,189 shares traded hands during mid-day trading, a decline of 47% from the average session volume of 23,127 shares. The stock had previously closed at $2.31.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised TherapeuticsMD from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, January 12th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat.com, the stock has an average rating of “Hold”.

TherapeuticsMD Stock Performance

The company has a market capitalization of $25.69 million, a PE ratio of -222.00 and a beta of 0.51. The company’s 50-day simple moving average is $2.31 and its 200-day simple moving average is $1.74.

Hedge Funds Weigh In On TherapeuticsMD

Several institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC raised its stake in TherapeuticsMD by 171.8% during the 4th quarter. Renaissance Technologies LLC now owns 96,500 shares of the company’s stock valued at $157,000 after acquiring an additional 61,000 shares during the last quarter. Tejara Capital Ltd grew its stake in shares of TherapeuticsMD by 1.9% in the 4th quarter. Tejara Capital Ltd now owns 350,852 shares of the company’s stock valued at $572,000 after purchasing an additional 6,649 shares during the last quarter. Finally, Citadel Advisors LLC grew its stake in shares of TherapeuticsMD by 125.5% in the 3rd quarter. Citadel Advisors LLC now owns 34,273 shares of the company’s stock valued at $36,000 after purchasing an additional 19,073 shares during the last quarter. Institutional investors and hedge funds own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.